Is HALO a buy? - Seeking Alpha

Quote & Headlines Market Currents StockTalk

Today 5d 1m 3m 1y 5y 10y

52wk high:

52wk low:

EPS:

PE:

Div Rate:

Yield:

Market Cap:

Volume:

1,032 people get HALO articles and Market Currents by email alert.

Get email alerts on HALO »

HEADLINES:

Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting

PR Newswire (Wed, 6:05PM)
Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Halozyme Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Halozyme Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 7, 2013)
Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
PropThink • Fri, May 3
Halozyme to Host First Quarter 2013 Financial Results Conference Call

PR Newswire (May 1, 2013)
Renewed Buying Interest In Halozyme After Phase II Initiation
Brian L. Wilson • Wed, Apr 24 • 1 Comment
Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer

PR Newswire (Apr 23, 2013)
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
PropThink • Wed, Apr 3
Halozyme Therapeutics Names Matt Posard to Board of Directors

PR Newswire (Mar 28, 2013)
Halozyme Rallies On Success In Europe, US Next Target
Brian L. Wilson • Tue, Mar 26
Last Week's Biotech Movers: Are Any A Buy?
Brian Nichols • Mon, Mar 25 • 16 Comments
Halozyme Is Attractive Again After EU Opinion On HyQvia
PropThink • Fri, Mar 22
Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union

PR Newswire (Mar 22, 2013)
Halozyme Therapeutics' Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
VIX - Options Volatility And Market Sonar: Monday Recap
Erick McKitterick • Mon, Mar 11 • 9 Comments
Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference

PR Newswire (Mar 5, 2013)
Halozyme Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 25
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results

PR Newswire (Feb 25, 2013)

To learn more about Seeking Alpha Pro, click here.

Renewed Buying Interest In Halozyme After Phase II Initiation
Brian L. Wilson • Wed, Apr 24 • 1 Comment
Halozyme Rallies On Success In Europe, US Next Target
Brian L. Wilson • Tue, Mar 26
Halozyme Is Attractive Again After EU Opinion On HyQvia
PropThink • Fri, Mar 22
Is Now The Time To Jump Into Halozyme?
John Eastman • Wed, Feb 13 • 3 Comments
Baxter's Earnings Call Reveals Good News For Halozyme
PropThink • Thu, Jan 24 • 4 Comments
The Upward Climb Of Halozyme Therapeutics
John Eastman • Mon, Jan 14
Halozyme Moving Higher On Fundamentals, Analyst Upgrade
PropThink • Mon, Jan 14 • 1 Comment
Pfizer Takes Interest In Halozyme's Biologics Platform
Brian L. Wilson • Wed, Jan 9 • 3 Comments
Halozyme Therapeutics's Key Deal With Pfizer Is Significant
John Eastman • Thu, Jan 3 • 1 Comment
Halozyme Therapeutics Set To Shine On Deal With Pfizer
PropThink • Fri, Dec 21, 2012
A Halo Comes Off
InsiderInsights • Mon, Apr 30, 2012 • 4 Comments
A Very Compelling Biopharmaceutical Investment
Steven Bulwa • Wed, Apr 18, 2012 • 13 Comments
Halozyme's New High
Jessica King Holden • Wed, Feb 1, 2012 • 1 Comment
Widespread Potential For Halozyme
Jessica King Holden • Tue, Jan 17, 2012
Halozyme Gets Good News From Roche's Subcutaneous Herceptin Phase 3 Trial
M. E. Garza • Wed, Oct 19, 2011
Halozyme Buoyed By Good Herceptin News
EP Vantage • Wed, Oct 19, 2011
Several Upcoming Catalysts In Play For Halozyme Therapeutics
Brian L. Wilson • Thu, Oct 13, 2011
Halozyme: It's All in the Delivery
Jason Chew • Sun, Jan 9, 2011 • 5 Comments

Despite Poor Quarter, ViroPharma's Commercial And Pipeline Progress Continue
PropThink • Fri, May 3
ViroPharma: Generic Concerns Overblown, Pipeline Will Bring Revenue Diversity
PropThink • Wed, Apr 3
Last Week's Biotech Movers: Are Any A Buy?
Brian Nichols • Mon, Mar 25 • 16 Comments
VIX - Options Volatility And Market Sonar: Monday Recap
Erick McKitterick • Mon, Mar 11 • 9 Comments
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Tue, Feb 5
4 Rallying Biotech Stocks Being Snapped Up By Insiders
Kapitall • Wed, Jan 16 • 2 Comments
VIX - Options Volatility Sonar: Monday Recap
Erick McKitterick • Mon, Jan 14 • 4 Comments
Insider Buying Trends: Are These Cash Rich Companies Ready To Rally?
Kapitall • Fri, Jan 4
5 Biotech Winners From Last Week With High Short Ratios
Heisenberg Principle • Mon, Dec 24, 2012
2 Biotech Stocks Worth Going Long On In The Wake Of Recent Developments
Matt Schilling • Fri, Dec 21, 2012 • 1 Comment
4 Promising Biotech Stocks To Consider Now
Cris Frangold • Wed, Dec 12, 2012 • 3 Comments
5 Healthcare Companies With Recent Insider Buying
Markus Aarnio • Thu, Nov 15, 2012
Investing In Novel Drug Delivery Ideas
Peter Geschek • Wed, Oct 3, 2012 • 3 Comments
Dyax And ViroPharma: An Overview Of HAE Space
LifeSci Advisors • Tue, Sep 18, 2012
Insider Buying Trends: Are These Cash-Rich Companies Ready For A Rally?
Kapitall • Tue, Sep 18, 2012 • 6 Comments
Analyst Greg Wade Bets On Extraordinary Science And Clinical Data
Life Sciences Report • Thu, Aug 30, 2012
5 Healthcare Companies With Insider Buying Filed On August 24 - 28
Markus Aarnio • Wed, Aug 29, 2012 • 2 Comments
Insiders Bought These Shares On August 28
StockPandit • Wed, Aug 29, 2012 • 2 Comments
Is Baxter A Bargain? Management Seems To Think So
Glen S. Woods • Tue, Aug 28, 2012 • 7 Comments
6 Cash-Heavy Biotech Stocks With Analyst Endorsements
ZetaKap • Thu, Aug 23, 2012

Halozyme Therapeutics Management Presents at Bank of America Merrill Lynch Health Care Conference (Transcript)
Wed, May 15
Halozyme Therapeutics Management Discusses Q1 2013 Results - Earnings Call Transcript
Wed, May 8
Halozyme Therapeutics' Management Presents at Barclays Global Healthcare Conference (Transcript)
Tue, Mar 12
Halozyme Therapeutics' CEO Discusses Q4 2012 Results - Earnings Call Transcript
Mon, Feb 25
Halozyme Therapeutics Management Discusses Q3 2012 Results - Earnings Call Transcript
Thu, Nov 8, 2012
Halozyme Therapeutics's CEO Hosts Analyst/Investor Day Conference Call (Transcript)
Tue, Oct 2, 2012
Halozyme Therapeutics Management Discusses Q2 2012 Results - Earnings Call Transcript
Mon, Aug 6, 2012
Halozyme Therapeutics, Inc. Q3 2009 Earnings Call Transcript
Fri, Nov 6, 2009
Halozyme Therapeutics, Inc. Q4 2008 Earnings Call Transcript
Fri, Mar 13, 2009
Halozyme Therapeutics, Inc. Q3 2008 Earnings Call Transcript
Wed, Nov 19, 2008
Halozyme Therapeutics Inc. Q2 2008 Earnings Call Transcript
Fri, Aug 8, 2008
Halozyme Therapeutics Inc. Q1 2008 Earnings Call Transcript
Fri, May 9, 2008
Halozyme Therapeutics Q4 2007 Earnings Call Transcript
Fri, Mar 14, 2008

Halozyme To Present New Data On PEGPH20 In Pancreatic Cancer At American Society of Clinical Oncology Annual Meeting

PR Newswire (Wed, 6:05PM)
Halozyme Reports First Quarter 2013 Financial Results

PR Newswire (May 8, 2013)
Halozyme Therapeutics To Present At The Bank Of America Merrill Lynch 2013 Health Care Conference

PR Newswire (May 7, 2013)
Halozyme to Host First Quarter 2013 Financial Results Conference Call

PR Newswire (May 1, 2013)
Halozyme Initiates Randomized Phase 2 Trial of PEGPH20 in Pancreatic Cancer

PR Newswire (Apr 23, 2013)
Halozyme Therapeutics Names Matt Posard to Board of Directors

PR Newswire (Mar 28, 2013)
Baxter And Halozyme Announce Positive Opinion For HyQvia For Treatment Of Primary And Secondary Immunodeficiencies In The European Union

PR Newswire (Mar 22, 2013)
Halozyme Therapeutics to Present at the Barclays 2013 Global Healthcare Conference

PR Newswire (Mar 5, 2013)
Halozyme Reports Fourth Quarter and Year End 2012 Financial Results

PR Newswire (Feb 25, 2013)
Halozyme to Host Fourth Quarter and 2012 Year-End Financial Results Conference Call

PR Newswire (Feb 19, 2013)
Halozyme Therapeutics Issues Financial Guidance For 2013

PR Newswire (Jan 7, 2013)
Halozyme Therapeutics to Present at the 31st Annual J.P. Morgan Healthcare Conference

PR Newswire (Jan 3, 2013)
Movers & Shakers: Friday’s biggest gaining and declining stocks

at MarketWatch.com (Dec 21, 2012)
Halozyme Therapeutics And Pfizer Enter Into A Collaboration To Develop And Commercialize Subcutaneous Biologics Using Recombinant Human Hyaluronidase

PR Newswire (Dec 21, 2012)
ViroPharma and Halozyme Therapeutics Announce Initiation of Phase 2b Dose Ranging Combination Study for Subcutaneous Administration of Cinryze® (C1 esterase inhibitor [human]) With Hyaluronidase (rHuPH20)

PR Newswire (Dec 19, 2012)
Halozyme Announced Roche Filed A Marketing Authorization Application For Subcutaneous MabThera

PR Newswire (Dec 8, 2012)
Halozyme Reports Third Quarter 2012 Financial Results

PR Newswire (Nov 8, 2012)
Halozyme Therapeutics To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

PR Newswire (Nov 6, 2012)
Halozyme to Host Third Quarter Financial Results Conference Call

PR Newswire (Nov 1, 2012)
Halozyme Therapeutics to Host Analyst / Investor Meeting on October 2nd in New York

PR Newswire (Sep 25, 2012)

HALO vs. ETF Alternatives

Company Description

Currently, there's no company description for HALO.

Sector: Healthcare

Industry: Biotechnology

Country: United States

All
| Earnings
| Dividends
| M&A
| On the move

Friday, May 17, 10:37 AM Halozyme Therapeutics (HALO +1%) continues its run again today, on the back of an 18% gain in yesterday's regular session. Late Wednesday, the company said that positive clinical data from a Phase 1b trial of PEGPH20 in combination with gemcitabine to treat patients with stage IV metastatic pancreatic cancer will be presented at the 2013 American Society of Clinical Oncology Annual Meeting. Comment! [Healthcare, On the Move]
Friday, May 17, 9:10 AM Premarket gainers: MHGC +20%. NBG +19%. JRCC +8%. HALO +6%. RKUS +5%.
Losers: ARUN -27%. ADSK -7%. Comment! [On the Move]
Thursday, May 16, 12:13 PM Wedbush doesn't find any love in Halozyme Therapeutics (HALO +16.6%) ASCO presentation earlier today regarding clinical data from a Phase 1b trial of PEGPH20 that showed it helps to break down pancreatic cancers. The firm says that a positive tumor response outcome was expected. However, serial comparative PET imaging is a potentially more biologically relevant measure of disease activity, and it continues to expect a negative recommendation from the EMA on the approval of sub-cu Herceptin in Q2. 1 Comment [Healthcare, On the Move]
Thursday, May 16, 9:18 AM Halozyme Therapeutics (HALO) jumps 7.57% premarket after saying Wednesday evening that data from a Phase 1b study supports the contention that PEGPH20 helps break down a protective matrix which surrounds most pancreatic cancers, making the disease more vulnerable to therapy. (PR) Comment! [Healthcare, On the Move]
Thursday, May 16, 9:14 AM Premarket gainers: RGDX +24%. EGLE +23%. EFUT +19%. TSLA +13%. CSCO +13%. SCTY +11%. DQ +9%. HALO +8%. DANG +7%. AV +7%. YRCW +8%. NBG +7%. KSS +7%. SPWR +6%.
Losers: NCT -53%. SNFCA -24%. AMD -10%. NQ -7%. CYCC -5%. Comment! [On the Move]
Wednesday, May 15, 7:32 AM Piper Jaffray starts Halozyme Therapeutics (HALO) at Overweight with a $10 price target. Analyst Charles Duncan says the company's hyaluronidase technology platform has been "validated by extensive partnerships, including some with large pharma and thought-leading biotechs." Comment! [Healthcare]
Wednesday, May 8, 4:57 PM More on Halozyme Therapeutics (HALO): Q1 comes in mixed, beating on its top line but coming up short on a per share basis. Total sales climbed by nearly 60% Y/Y, driven by R&D reimbursements from partners primarily related to manufacturing activities to support potential launches. R&D expenses related to those activities also rose however, which, along with an increase in clinical trial activities, contributed to the bottom line shortfall. Comment! [Healthcare, Earnings]
Wednesday, May 8, 4:21 PM Halozyme Therapeutics (HALO): Q1 EPS of -$0.17 misses by $0.02. Revenue of $11.8M beats by $4.75M. (PR) Comment! [Earnings, Breaking News, Healthcare]
Wednesday, May 8, 12:10 AM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
Tuesday, May 7, 5:35 PM Notable earnings after Wednesday’s close: AHT, ALJ, ATLS, ATVI, AVNR, CF, CLNE, CLR, CTL, CTRP, CUZ, CXW, DEPO, DK, ERII, ETE, ETP, GMCR, GRPN, GSS, HALO, HEK, HNSN, JOE, LPSN, MBLX, MDR, MED, MIDD, MM, MNST, MNTX, MWE, NWSA, OSUR, PPO, PVA, QTM, RAX, RGP, RIG, RST, SGMO, SPRD, SSRI, STEC, SXL, SZYM, TCAP, TSLA, WR, XTEX Comment! [Earnings]
Wednesday, May 1, 5:37 PM After-hours top gainers, as of 5:15 p.m.: IFT +27%. REGI +18%. YELP +10%. HALO +8%. ISSI +7%.
After-hours top losers: NSPR -7%. GTAT -7%. BRCD -5%. GLUU -5%. CNW -4%. Comment! [On the Move]
Wednesday, May 1, 3:24 PM A number of biotechs are sharply lower amid rumors of a sizable Bio-fund going out of business and liquidating its positions. It's Ayer Capital Management according to sources, reports Adam Feuerstein. (PCYC -5.6%), (CLDX -4.9%), (NPSP -3.1%), (HALO -3.8%). 6 Comments [Healthcare, On the Move]
Thursday, March 28, 4:33 PM Halozyme Therapeutics (HALO) says it's appointed Matt Posard to its Board of Directors. Mr. Posard is currently SVP and General Manager of Translational & Consumer Genomics at Illumina (ILMN). Shares +0.2% AH Comment! [Healthcare]
Friday, March 22, 9:29 AM Halozyme Therapeutics (HALO) +18.6% premarket after the European Medicines Agency approves partner Baxter (BAX) for the use of HALO's HyQvia as replacement therapy for adult patients with primary and secondary immunodeficiencies. Upon receiving marketing authorization from the EC, BAX plans to launch HyQvia in some European countries later this year. Comment! [Healthcare, On the Move]
Friday, March 22, 9:10 AM Premarket gainers: HALO +23%. ANAC +18%. MU +9%. AFFY +8%. NKE +8%.
Losers: TIBX -16%. ABR -6%. ZIOP -5%. Comment! [On the Move]
Monday, February 25, 4:10 PM Halozyme Therapeutics (HALO): Q4 EPS of -$0.04 beats by $0.12. Revenue of $21.8M beats by $. Shares +3.3% AH. (PR) Comment! [Earnings, Breaking News, Healthcare, On the Move]

Brian L. Wilson
Anyone interested in what $PFE is up to, check out my article on $HALO http://seekingalpha.com/a/nnff
Jan 9, 3:57 PM
Reply (2)

• !Report Abuse
View all 2 replies
Hillbilly Stock Star: + Hef got married, Long $PFE
Jan 9, 4:10 PM
• !Report Abuse
make$work4u: lol
Jan 9, 4:26 PM
• !Report Abuse
Add a reply...

140 characters

Joe Springer
Happy Halloween everyone! I'm going as a cash secured put! : ) http://goo.gl/zv9GE $BOO $SCAR $HALO $HELL $CNDY $KNDI $GHST #Enron #Scary
10/31/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

The Berenstain Bulls
I imagine that there will be records sales records set with the release of HALO 4 (it's literally the only thing I want to Christmas).
10/23/12
Reply (8)

• !Report Abuse
View all 8 replies
The Berenstain Bulls: It is unreal, honestly, it's probably the best game I've ever played. Everything runs so smoothly, it's awesome. The way they set up
11/9/12
• !Report Abuse
The Berenstain Bulls: everything is great also.
11/9/12
• !Report Abuse
Add a reply...

140 characters

freefdawatchlist
http://stks.co/iC8S ECB is carrying fine tuning operation tomorrow don't be surprise with higher open.Stocks to watch $AAPL $FAS $SPY $HALO
10/1/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

ZetaKap
6 Cash-Heavy Biotech Stocks With Analyst Endorsements http://bit.ly/TXLKnB $CYTX $PLX $GTXI $HALO $ILMN $THRX @ZetaKap
8/23/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

lorenziero
Sometime in the near future I hope HALO execs provide real clarity on what the CRL says about the company's platform technology.
8/5/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

realornot
Plenty of room for NFLX to drop..... It is a HALO drop. Are you ready!?
5/4/12
Reply (4)

• !Report Abuse
View all 4 replies
Josh Krause: Strong rebound in NFLX. They might try to close it green or flat. If so, squeeze would likely follow. Agree?
5/4/12
• !Report Abuse
Josh Krause: Closing in on green. Going to be a massive hammer on the daily chart.
5/4/12
• !Report Abuse
Add a reply...

140 characters

Michael Bryant
This week's Momentum Option's Trading pick is Halozyme Therapeutics (HALO). Weekly Wrap newsletter is 16-0. http://bit.ly/eIvFSG
1/17/12
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

Kinetic Investments
HALO - Big insider buys - http://bit.ly/twbzQ7
11/25/11
Reply

• !Report Abuse
View all 0 replies
Add a reply...

140 characters

LATEST REPLIES

Brian L. Wilson
Anyone interested in what $PFE is up to, check out my article on $HALO http://seekingalpha.com/a/nnff
Jan 9, 3:57 PM
Reply (2)

• !Report Abuse
View all 2 replies
Hillbilly Stock Star: + Hef got married, Long $PFE
Jan 9, 4:10 PM
• !Report Abuse
make$work4u: lol
Jan 9, 4:26 PM
• !Report Abuse
Add a reply...

140 characters

The Berenstain Bulls
I imagine that there will be records sales records set with the release of HALO 4 (it's literally the only thing I want to Christmas).
10/23/12
Reply (8)

• !Report Abuse
View all 8 replies
The Berenstain Bulls: It is unreal, honestly, it's probably the best game I've ever played. Everything runs so smoothly, it's awesome. The way they set up
11/9/12
• !Report Abuse
The Berenstain Bulls: everything is great also.
11/9/12
• !Report Abuse
Add a reply...

140 characters

realornot
Plenty of room for NFLX to drop..... It is a HALO drop. Are you ready!?
5/4/12
Reply (4)

• !Report Abuse
View all 4 replies
Josh Krause: Strong rebound in NFLX. They might try to close it green or flat. If so, squeeze would likely follow. Agree?
5/4/12
• !Report Abuse
Josh Krause: Closing in on green. Going to be a massive hammer on the daily chart.
5/4/12
• !Report Abuse
Add a reply...

140 characters

HALO Halozyme Therapeutics, Inc.

HALO

Halozyme Therapeutics, Inc.